Aparna Hegde

Aparna Hegde

Auto-generated profile, based on publicly available information

Aparna Hegde

Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PMPrashant Kumar Modi
Prashant Kumar Modi
APAshwini Prabhu
Ashwini Prabhu
YBYashodhar P. Bhandary
Yashodhar P. Bhandary
SPSudheer Shenoy P
Sudheer Shenoy P
AHAparna Hegde
Aparna Hegde
PRPD Rekha
PD Rekha
Calcium is the key macromineral having a role in skeletal structure and function, muscle contraction, and neurotransmission. Bone remodeling is maintained through a constant balance between calcium resorption and deposition. Calcium deficiency is resolved through calcium supplementation, and among the supplements, water-soluble organic molecules attracted great pharmaceutical interest. Calcium glucoheptonate is a highly water-soluble organic calcium salt having clinical use; however, detailed investigations on its biological effects are limited. We assessed the effects of calcium glucoheptonate on cell viability and proliferation of osteoblast-like MG-63 cells. Calcium uptake and mineralization were evaluated using Alizarin red staining of osteoblast-like MG-63 cells treated with calcium glucoheptonate. Expression of osteogenic markers were monitored by western blotting, immunofluorescence, and qRT-PCR assays. Increased proliferation and calcium uptake were observed in the MG-63 cells treated with calcium glucoheptonate. The treatment also increased the expression of osteopontin and osteogenic genes such as collagen-1, secreted protein acidic and cysteine rich (SPARC), and osteocalcin. Calcium glucoheptonate treatment did not exert any cytotoxicity on colorectal and renal epithelial cells, indicating the safety of the treatment. This is the first report with evidence for its beneficial effect for pharmaceutical use in addressing calcium deficiency conditions.

20 September 2018 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
MIMohamed Ismail
Mohamed Ismail
DNDileep Nagaraj
Dileep Nagaraj
MRMahesh Rajagopal
Mahesh Rajagopal
HAHafiz Ansari
Hafiz Ansari
MNMegha Nair
Megha Nair
PRPD Rekha
PD Rekha

20 April 2018 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
MKManish Khaitan
Manish Khaitan
AHAparna Hegde
Aparna Hegde
PRPD Rekha
PD Rekha

1 April 2021 in Journal of Minimal Access Surgery
Verified
Journal Article
Open access
MIMohamed Ismail
Mohamed Ismail
DNDileep Nagaraj
Dileep Nagaraj
MRMahesh Rajagopal
Mahesh Rajagopal
HAHafiz Ansari
Hafiz Ansari
KIKingsly Iyyankutty
Kingsly Iyyankutty
PRP. D. Rekha
P. D. Rekha
Background: Laparoscopic Roux-en-Y gastric bypass (RYGB) has been proven to induce significant weight loss and remission of related co-morbidities in patients with morbid obesity. The long-term follow-up data show weight regain or failure to achieve complete remission of type 2 diabetes mellitus (T2DM) in some patients. In this study, we report weight loss patterns and remission of T2DM in patients with morbid obesity during a 5-year follow-up after RYGB. Objective: The objective was to evaluate outcomes during the follow-up on excess weight loss (EWL) and remission of T2DM after laparoscopic RYGB among Indian patients. Setting: The study was conducted in a tertiary care hospital, Kerala, India. Materials and Methods: This is a retrospective study in patients who underwent surgery between 2007 and 2010. The patient demographics, pre- and post-operative body mass index (BMI), co-morbidities and EWL were recorded from the medical records. These data were compared between pre-operative and follow-up intervals till 5 years using statistical approaches. Results: The study included 157 patients (91 males and 66 females) having a mean pre-operative BMI of 47.91 ± 7.01 kg/m2. A significant reduction in the BMI was observed at each follow-up point (P < 0.01) till 5 years after the surgery. The mean percentage of EWL increased from 34.57% ± 12.62% to 71.50% ± 15.41% from 3 months to 5 years after the surgery. Twelve per cent (n = 19) of patients achieved normal BMI (50% of patients within a year of surgery. During the 5th year, weight regain (1–22 kg) was observed in 36.70% (n = 58) patients, and recurrence of T2DM was observed in two patients. Conclusions: The long-term durability of RYGB in the study population was satisfactory with significant weight loss and remission of T2DM.

29 May 2021 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
RGRiddhish Gadani
Riddhish Gadani
MKManish Khaitan
Manish Khaitan
PRPD Rekha
PD Rekha
AHAparna Hedge
Aparna Hedge
KPKoshish Nandan Pokharel
Koshish Nandan Pokharel
VKVinay Khatri
Vinay Khatri

19 March 2020 in Indian Journal of Surgery
Verified
Journal Article
Closed access
PDF file
JAJ. B. Agrawal
J. B. Agrawal
AHAparna Hegde
Aparna Hegde
PRPD Rekha
PD Rekha